Analysis of serum soluble CD40 ligand (sCD40L) in the patients undergoing allogeneic stem cell transplantation: Platelet is a major source of serum sCD40L

European Journal of Haematology

Volumn 74, Issue 1, 2005, Pages 54-60

  Nagasawa, Masayuki ^a   Zhu, Yi ^a   Isoda, Takeshi ^a   Tomizawa, Daisuke ^a   Itoh, Sukeyuki ^a   Kajiwara, Michiko ^a   Morio, Tomohiro ^a   Nonoyama, Shigeaki ^a   Shimizu, Norio ^a   Mizutani, Shuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Hyper IgM syndrome; Platelet; Soluble CD40 ligand; Soluble IL2R; Stem cell transplantation

Indexed keywords

CD40 LIGAND; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; METHYLPREDNISOLONE; SOLUBLE CD40 LIGAND; SOLUBLE INTERLEUKIN 2 RECEPTOR; TACROLIMUS; UNCLASSIFIED DRUG;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; GRAFT VERSUS HOST REACTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SERUM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOCYTOPENIC PURPURA; THROMBOCYTOPOIESIS; UNSTABLE ANGINA PECTORIS;

ADOLESCENT; ADULT; BLOOD PLATELETS; CD40 LIGAND; CHILD; CHILD, PRESCHOOL; CORD BLOOD STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; HYPERGAMMAGLOBULINEMIA; IMMUNOGLOBULIN M; INFANT; LYMPHOCYTE ACTIVATION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLATELET COUNT; RECEPTORS, INTERLEUKIN-2; SOLUBILITY; T-LYMPHOCYTES; THROMBOPOIESIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 19944434056     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2004.00342.x     Document Type: Article

References (27)

1. CALLARD RE, ARMITAGE RJ, FANSLOW WC, SPRIGGS MK. CD40 ligand and its role in X-linked hyper-IgM syndrome. Immunol Today 1993;14:559-564.
2. INWALD DP, PETERS MJ, WALSHE D. JONES A, DAVIES EG, KLEIN NJ. Absence of platelet CD40L identifies patients with X-linked hyper IgM syndrome. Clin Exp Immunol 2000;120:499-502.
3. LEVY J, ESPANOL-BOREN T, THOMAS C, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997;131:47-54.
4. BORDIGONI P, AUBURTIN B, CARRET AS, SCHUHMACHER A, HUMBERT JC, LE DEIST F, SOMMELET D. Bone marrow transplantation as treatment for X-linked immunodeficiency with hyper-IgM. Bone Marrow Transplant 1998;22:1111-1114.
5. MACH F, SCHONBECK U, SUKHOVA GK, BOURCIER T, BONNEFOY JY, POBER JS, LIBBY P. Functional CD40 ligands is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl Acad. Sci. U. S. A. 1997;94:1931-1936.
6. ANAND SX, VILES-GONZALEZ JF, BADIMON JJ, CAVUSOGLU E, MARMUR JD. Membrane-associated CD40L and sCD40L in atherothrombotic disease. Thromb Haemost 2003;90:377-384.
7. HENN V, SLUPSKY JR, GRAFE M, ANAGNOSTOPOULOS I, FORSTER R, MULLER-BERGHAUS G, KROCZEK RA. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998;391:591-594.
8. JIN Y, NONOYAMA S, MORIO T, IMAI K. OCHS HD, MIZUTANI S. Characterization of soluble CD40 ligand released from human activated platelets. J Med Dent Sci 2001;48:23-27.
9. NANNIZZI-ALAIMO L, ALVES VL, PHILLIPS DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003;107:1123-1128.
10. NAGASAWA M, ITOH S, SAWADA Y, MORIO T, NONOYAMA S, MIZUTANI S. Coagulopathy in a patient with X-linked hyper-IgM syndrome who developed Kaposi's sarcoma. Am J Hematol 2004;75:116-117.
11. WYKES M, POUDRIER J, LINDSTEDT R, GRAY D. Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells. Eur J Immunol 1998;28:548-559.
12. VAKKALANKA RK, WOO C, KIROU KA, KOSHY M, BERGER D, CROW MK. Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 1999;42:871-881.
13. AUKRUST P, MULLER F, UELAND T, BERGET T, AASER E, BRUNSVIG A, SOLUM NO, FORFANG K, FROLAND SS, GULLESTAD L. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999;100:614-620.
14. VIALLARD JF, SOLANILLA A, GAUTHIER B, et al. Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis. Blood 2002;99:2612-2614.
15. NAGAHAMA M, NOMURA S, KANAZAWA S, OZAKI Y, KAGAWA H, FUKUHARA S. Significance of chemokines and soluble CD40 ligand in patients with autoimmune thrombocytopenic purpura. Eur J Haematol 2002;69:303-308.
16. NANNIZZI-ALAIMO L, RUBENSTEIN MH. ALVES VL, LEONG GY. PHILLIP DR, GOLD HK. Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 2002;105:2849-2854.
17. PHILIPPS RP, KAUFMAN J, BLUMBERG N. Platelet derived CD154(CD40 ligand) and febrile responses to transfusion. Lancet 2001;357:2023-2024.
18. TOMIZAWA D, IMAI K, ITOH S, KAJIWARA M, MINEGISHI Y, NAGASAWA M, MORIO T, NONOYAMA S, MIZUTANI S. Allogenic hematopoietic stem cell transplantation for seven children with X-linked hyper-IgM syndrome: a single center experience American. J Hematol 2004;76:33-39.
19. CIPOLLONE F, MEZZETTI A, PORRECA E, DI FEBBO C, NUTINI M, FAZIA M, FALCO A, CUCCURULLO F, DAVI G. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation 2002;106:399-402.
20. MELLEMBAKKEN JR, SOLUM NO, UELAND T, VIDEM V, AUKRUST P. Increased concentrations of soluble CD40 ligand, RANTES and GRO-alpha in preeclampsia - possible role of platelet activation. Thromb Haemost 2001;86:1272-1276.
21. RUBIN LA, GALLI F, GREENE WC, NELSON DL, JAY G. The molecular basis for the generation of the human soluble interleukin 2 receptor. Cytokine 1990;2:330-336.
22. CHOPRA RK, POWERS DC, KENDIG NE, ADLER WH, NAGEL JE. Soluble interleukin 2 receptors released from mitogen stimulated human peripheral blood lymphocytes bind interleukin 2 and inhibit IL2 dependent cell proliferation. Immunol Invest 1989;18:961-973.
23. GABRIELLI A, MARROZZINI C, CANDELA M, FERRETTI RM, RECCHIONI A, BINETTI GF, DANIELI G. Prognostic significance of basement membrane antigens and of soluble interleukin 2 receptor serum concentrations in heart transplant rejection. Cardiologia 1994;39:481-486.
24. NINOVA DI, WIESNER RH, GORES GJ, HARRISON JM, KROM RA, HOMBURGER HA. Soluble T lymphocyte markers in the diagnosis of cellular rejection and cytomegalovirus hepatitis in liver transplant recipients. J Hepatol 1994;21:1080-1085.
25. DANESE S, KATZ JA, SAIBENI S, PAPA A, GASBARRINI A, VECCHI M, FIOCCHI C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 2003;52:1435-1441.
26. PIQUET PF, KAN CD, VESIN C. Thrombocytopenia in an animal model of malaria is associated with an increased caspase-mediated death of thrombocytes. Apoptosis 2002;7:91-98.
27. ODA A, OCHS HD. Wiskott-Aldrich syndrome protein and platelets. Immunol Rev 2000;178:111-117.